GSK's finance chief told he cannot leave China
July 18, 2013, Thursday
|
Print Edition
Print Edition
China is preventing GlaxoSmithKline's head of finance for China from leaving the country, as police accuse the British drugmaker of bribing officials and doctors, a spokesman for the company said yesterday.
The travel restriction on Steve Nechelput was imposed at the end of June, since when he has continued to carry out his work and remains free to move around the country. He has not been questioned, arrested or detained by police, the spokesman added.
Police have accused GSK of transferring up to 3 billion yuan (US$489 million) to 700 travel agencies and consultancies over six years to facilitate a campaign of corruption. In response, GSK said it was deeply concerned by the allegations, which it called "shameful."
The action against Nechelput, a British national, underscores the pressure on GSK, as China launched a crackdown on the pharmaceutical sector.
A British foreign ministry spokesman said it stood ready to provide consular assistance. Asked if London was concerned about the travel restriction, he added: "If there's an inquiry under way then that's a matter for the Chinese authorities."
Nechelput's boss Mark Reilly, GSK's general manager for China, left the country for Britain on July 5 to attend a series of "routine meetings."
Four senior Chinese executives from GSK have been detained by police, including vice president and operations manager Liang Hong, who told China Central Television on Tuesday he had funneled money through travel agencies by arranging conferences, some of which were never held.
With investigations focused on malpractice by certain of GSK's Chinese employees, one industry insider said it was likely China wanted Nechelput to remain in the country to provide financial information, if needed, as inquiries progress.
China has long been known for a culture in which drug companies make payments to doctors, since physicians rely on rewards for writing prescriptions to offset meager salaries.
Those practices, however, are increasingly at odds with a crackdown on corruption, leaving companies struggling to toe the line while not forgoing business in a highly competitive market.
Gao Feng, head of the economic crimes investigation unit at China's Ministry of Public Security, said this week similar money transfers to those seen at GSK had been made by other multinational pharmaceutical companies in China.
He did not name any other foreign companies.
When asked, the following major drugmakers denied they had been contacted by Chinese authorities in connection with similar bribery allegations: Novartis, Roche, Abbott, Eli Lilly, Bayer, Novo Nordisk, Takeda and Astellas.
China is increasingly important for drug groups, which rely on growth in emerging markets to offset slower sales in Western countries where many former top-selling medicines have lost patent protection.
IMS Health, which tracks pharmaceutical industry trends, expects China to overtake Japan as the world's second-biggest drugs market behind the United States by 2016.
Separately, GSK said its Chief Executive Andrew Witty was stepping down from his role on the board of the UK government's department for business at the end of 2013, as had always been planned.
The travel restriction on Steve Nechelput was imposed at the end of June, since when he has continued to carry out his work and remains free to move around the country. He has not been questioned, arrested or detained by police, the spokesman added.
Police have accused GSK of transferring up to 3 billion yuan (US$489 million) to 700 travel agencies and consultancies over six years to facilitate a campaign of corruption. In response, GSK said it was deeply concerned by the allegations, which it called "shameful."
The action against Nechelput, a British national, underscores the pressure on GSK, as China launched a crackdown on the pharmaceutical sector.
A British foreign ministry spokesman said it stood ready to provide consular assistance. Asked if London was concerned about the travel restriction, he added: "If there's an inquiry under way then that's a matter for the Chinese authorities."
Nechelput's boss Mark Reilly, GSK's general manager for China, left the country for Britain on July 5 to attend a series of "routine meetings."
Four senior Chinese executives from GSK have been detained by police, including vice president and operations manager Liang Hong, who told China Central Television on Tuesday he had funneled money through travel agencies by arranging conferences, some of which were never held.
With investigations focused on malpractice by certain of GSK's Chinese employees, one industry insider said it was likely China wanted Nechelput to remain in the country to provide financial information, if needed, as inquiries progress.
China has long been known for a culture in which drug companies make payments to doctors, since physicians rely on rewards for writing prescriptions to offset meager salaries.
Those practices, however, are increasingly at odds with a crackdown on corruption, leaving companies struggling to toe the line while not forgoing business in a highly competitive market.
Gao Feng, head of the economic crimes investigation unit at China's Ministry of Public Security, said this week similar money transfers to those seen at GSK had been made by other multinational pharmaceutical companies in China.
He did not name any other foreign companies.
When asked, the following major drugmakers denied they had been contacted by Chinese authorities in connection with similar bribery allegations: Novartis, Roche, Abbott, Eli Lilly, Bayer, Novo Nordisk, Takeda and Astellas.
China is increasingly important for drug groups, which rely on growth in emerging markets to offset slower sales in Western countries where many former top-selling medicines have lost patent protection.
IMS Health, which tracks pharmaceutical industry trends, expects China to overtake Japan as the world's second-biggest drugs market behind the United States by 2016.
Separately, GSK said its Chief Executive Andrew Witty was stepping down from his role on the board of the UK government's department for business at the end of 2013, as had always been planned.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
